Opioid Induced Constipation Drugs-Global Market Status and Trend Report 2013-2023
![](/report_cover/10724/opioid-induced-constipation-drugs-global-market-status-n-trend-report-2013-2023_en.gif)
Report Summary
Opioid Induced Constipation Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Opioid Induced Constipation Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Opioid Induced Constipation Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Opioid Induced Constipation Drugs worldwide, with company and product introduction, position in the Opioid Induced Constipation Drugs market
Market status and development trend of Opioid Induced Constipation Drugs by types and applications
Cost and profit status of Opioid Induced Constipation Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Opioid Induced Constipation Drugs market as:
Global Opioid Induced Constipation Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Opioid Induced Constipation Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Other
Global Opioid Induced Constipation Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Opioid Induced Constipation Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Opioid Induced Constipation Drugs Sales Volume, Revenue, Price and Gross Margin):
Ironwood Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Pfizer
Progenics Pharmaceuticals Inc
Shionogi & Co., Ltd
Allergan Plc
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma AG
Mundipharma International Limited
Ono Pharmaceutical Co., Ltd
Takeda Pharmaceutical Company Limited
Theravance Biopharma Inc
Valeant Pharmaceuticals International
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Opioid Induced Constipation Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Opioid Induced Constipation Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Opioid Induced Constipation Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Opioid Induced Constipation Drugs worldwide, with company and product introduction, position in the Opioid Induced Constipation Drugs market
Market status and development trend of Opioid Induced Constipation Drugs by types and applications
Cost and profit status of Opioid Induced Constipation Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Opioid Induced Constipation Drugs market as:
Global Opioid Induced Constipation Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Opioid Induced Constipation Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Other
Global Opioid Induced Constipation Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Opioid Induced Constipation Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Opioid Induced Constipation Drugs Sales Volume, Revenue, Price and Gross Margin):
Ironwood Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Pfizer
Progenics Pharmaceuticals Inc
Shionogi & Co., Ltd
Allergan Plc
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma AG
Mundipharma International Limited
Ono Pharmaceutical Co., Ltd
Takeda Pharmaceutical Company Limited
Theravance Biopharma Inc
Valeant Pharmaceuticals International
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF OPIOID INDUCED CONSTIPATION DRUGS
1.1 Definition of Opioid Induced Constipation Drugs in This Report
1.2 Commercial Types of Opioid Induced Constipation Drugs
1.2.1 Lubiprostone
1.2.2 Methyl Naltrexone Bromide
1.2.3 Naldemedine
1.2.4 Alvimopan
1.2.5 Other
1.3 Downstream Application of Opioid Induced Constipation Drugs
1.3.1 Hospital Pharmacies
1.3.2 Retail Pharmacies
1.3.3 Online Pharmacies
1.4 Development History of Opioid Induced Constipation Drugs
1.5 Market Status and Trend of Opioid Induced Constipation Drugs 2013-2023
1.5.1 Global Opioid Induced Constipation Drugs Market Status and Trend 2013-2023
1.5.2 Regional Opioid Induced Constipation Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Opioid Induced Constipation Drugs 2013-2017
2.2 Sales Market of Opioid Induced Constipation Drugs by Regions
2.2.1 Sales Volume of Opioid Induced Constipation Drugs by Regions
2.2.2 Sales Value of Opioid Induced Constipation Drugs by Regions
2.3 Production Market of Opioid Induced Constipation Drugs by Regions
2.4 Global Market Forecast of Opioid Induced Constipation Drugs 2018-2023
2.4.1 Global Market Forecast of Opioid Induced Constipation Drugs 2018-2023
2.4.2 Market Forecast of Opioid Induced Constipation Drugs by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Opioid Induced Constipation Drugs by Types
3.2 Sales Value of Opioid Induced Constipation Drugs by Types
3.3 Market Forecast of Opioid Induced Constipation Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Opioid Induced Constipation Drugs by Downstream Industry
4.2 Global Market Forecast of Opioid Induced Constipation Drugs by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Opioid Induced Constipation Drugs Market Status by Countries
5.1.1 North America Opioid Induced Constipation Drugs Sales by Countries (2013-2017)
5.1.2 North America Opioid Induced Constipation Drugs Revenue by Countries (2013-2017)
5.1.3 United States Opioid Induced Constipation Drugs Market Status (2013-2017)
5.1.4 Canada Opioid Induced Constipation Drugs Market Status (2013-2017)
5.1.5 Mexico Opioid Induced Constipation Drugs Market Status (2013-2017)
5.2 North America Opioid Induced Constipation Drugs Market Status by Manufacturers
5.3 North America Opioid Induced Constipation Drugs Market Status by Type (2013-2017)
5.3.1 North America Opioid Induced Constipation Drugs Sales by Type (2013-2017)
5.3.2 North America Opioid Induced Constipation Drugs Revenue by Type (2013-2017)
5.4 North America Opioid Induced Constipation Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Opioid Induced Constipation Drugs Market Status by Countries
6.1.1 Europe Opioid Induced Constipation Drugs Sales by Countries (2013-2017)
6.1.2 Europe Opioid Induced Constipation Drugs Revenue by Countries (2013-2017)
6.1.3 Germany Opioid Induced Constipation Drugs Market Status (2013-2017)
6.1.4 UK Opioid Induced Constipation Drugs Market Status (2013-2017)
6.1.5 France Opioid Induced Constipation Drugs Market Status (2013-2017)
6.1.6 Italy Opioid Induced Constipation Drugs Market Status (2013-2017)
6.1.7 Russia Opioid Induced Constipation Drugs Market Status (2013-2017)
6.1.8 Spain Opioid Induced Constipation Drugs Market Status (2013-2017)
6.1.9 Benelux Opioid Induced Constipation Drugs Market Status (2013-2017)
6.2 Europe Opioid Induced Constipation Drugs Market Status by Manufacturers
6.3 Europe Opioid Induced Constipation Drugs Market Status by Type (2013-2017)
6.3.1 Europe Opioid Induced Constipation Drugs Sales by Type (2013-2017)
6.3.2 Europe Opioid Induced Constipation Drugs Revenue by Type (2013-2017)
6.4 Europe Opioid Induced Constipation Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Opioid Induced Constipation Drugs Market Status by Countries
7.1.1 Asia Pacific Opioid Induced Constipation Drugs Sales by Countries (2013-2017)
7.1.2 Asia Pacific Opioid Induced Constipation Drugs Revenue by Countries (2013-2017)
7.1.3 China Opioid Induced Constipation Drugs Market Status (2013-2017)
7.1.4 Japan Opioid Induced Constipation Drugs Market Status (2013-2017)
7.1.5 India Opioid Induced Constipation Drugs Market Status (2013-2017)
7.1.6 Southeast Asia Opioid Induced Constipation Drugs Market Status (2013-2017)
7.1.7 Australia Opioid Induced Constipation Drugs Market Status (2013-2017)
7.2 Asia Pacific Opioid Induced Constipation Drugs Market Status by Manufacturers
7.3 Asia Pacific Opioid Induced Constipation Drugs Market Status by Type (2013-2017)
7.3.1 Asia Pacific Opioid Induced Constipation Drugs Sales by Type (2013-2017)
7.3.2 Asia Pacific Opioid Induced Constipation Drugs Revenue by Type (2013-2017)
7.4 Asia Pacific Opioid Induced Constipation Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Opioid Induced Constipation Drugs Market Status by Countries
8.1.1 Latin America Opioid Induced Constipation Drugs Sales by Countries (2013-2017)
8.1.2 Latin America Opioid Induced Constipation Drugs Revenue by Countries (2013-2017)
8.1.3 Brazil Opioid Induced Constipation Drugs Market Status (2013-2017)
8.1.4 Argentina Opioid Induced Constipation Drugs Market Status (2013-2017)
8.1.5 Colombia Opioid Induced Constipation Drugs Market Status (2013-2017)
8.2 Latin America Opioid Induced Constipation Drugs Market Status by Manufacturers
8.3 Latin America Opioid Induced Constipation Drugs Market Status by Type (2013-2017)
8.3.1 Latin America Opioid Induced Constipation Drugs Sales by Type (2013-2017)
8.3.2 Latin America Opioid Induced Constipation Drugs Revenue by Type (2013-2017)
8.4 Latin America Opioid Induced Constipation Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Opioid Induced Constipation Drugs Market Status by Countries
9.1.1 Middle East and Africa Opioid Induced Constipation Drugs Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Opioid Induced Constipation Drugs Revenue by Countries (2013-2017)
9.1.3 Middle East Opioid Induced Constipation Drugs Market Status (2013-2017)
9.1.4 Africa Opioid Induced Constipation Drugs Market Status (2013-2017)
9.2 Middle East and Africa Opioid Induced Constipation Drugs Market Status by Manufacturers
9.3 Middle East and Africa Opioid Induced Constipation Drugs Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Opioid Induced Constipation Drugs Sales by Type (2013-2017)
9.3.2 Middle East and Africa Opioid Induced Constipation Drugs Revenue by Type (2013-2017)
9.4 Middle East and Africa Opioid Induced Constipation Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF OPIOID INDUCED CONSTIPATION DRUGS
10.1 Global Economy Situation and Trend Overview
10.2 Opioid Induced Constipation Drugs Downstream Industry Situation and Trend Overview
CHAPTER 11 OPIOID INDUCED CONSTIPATION DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Opioid Induced Constipation Drugs by Major Manufacturers
11.2 Production Value of Opioid Induced Constipation Drugs by Major Manufacturers
11.3 Basic Information of Opioid Induced Constipation Drugs by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Opioid Induced Constipation Drugs Major Manufacturer
11.3.2 Employees and Revenue Level of Opioid Induced Constipation Drugs Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 OPIOID INDUCED CONSTIPATION DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Ironwood Pharmaceuticals Inc
12.1.1 Company profile
12.1.2 Representative Opioid Induced Constipation Drugs Product
12.1.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Ironwood Pharmaceuticals Inc
12.2 Daiichi Sankyo Co Ltd
12.2.1 Company profile
12.2.2 Representative Opioid Induced Constipation Drugs Product
12.2.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Daiichi Sankyo Co Ltd
12.3 Pfizer
12.3.1 Company profile
12.3.2 Representative Opioid Induced Constipation Drugs Product
12.3.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Pfizer
12.4 Progenics Pharmaceuticals Inc
12.4.1 Company profile
12.4.2 Representative Opioid Induced Constipation Drugs Product
12.4.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Progenics Pharmaceuticals Inc
12.5 Shionogi & Co., Ltd
12.5.1 Company profile
12.5.2 Representative Opioid Induced Constipation Drugs Product
12.5.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Shionogi & Co., Ltd
12.6 Allergan Plc
12.6.1 Company profile
12.6.2 Representative Opioid Induced Constipation Drugs Product
12.6.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Allergan Plc
12.7 Nektar Therapeutics
12.7.1 Company profile
12.7.2 Representative Opioid Induced Constipation Drugs Product
12.7.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Nektar Therapeutics
12.8 Purdue Pharma
12.8.1 Company profile
12.8.2 Representative Opioid Induced Constipation Drugs Product
12.8.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Purdue Pharma
12.9 S.L.A. Pharma AG
12.9.1 Company profile
12.9.2 Representative Opioid Induced Constipation Drugs Product
12.9.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of S.L.A. Pharma AG
12.10 Mundipharma International Limited
12.10.1 Company profile
12.10.2 Representative Opioid Induced Constipation Drugs Product
12.10.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Mundipharma International Limited
12.11 Ono Pharmaceutical Co., Ltd
12.11.1 Company profile
12.11.2 Representative Opioid Induced Constipation Drugs Product
12.11.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Ono Pharmaceutical Co., Ltd
12.12 Takeda Pharmaceutical Company Limited
12.12.1 Company profile
12.12.2 Representative Opioid Induced Constipation Drugs Product
12.12.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Takeda Pharmaceutical Company Limited
12.13 Theravance Biopharma Inc
12.13.1 Company profile
12.13.2 Representative Opioid Induced Constipation Drugs Product
12.13.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Theravance Biopharma Inc
12.14 Valeant Pharmaceuticals International
12.14.1 Company profile
12.14.2 Representative Opioid Induced Constipation Drugs Product
12.14.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Valeant Pharmaceuticals International
12.15 Cosmo Pharmaceuticals SA
12.15.1 Company profile
12.15.2 Representative Opioid Induced Constipation Drugs Product
12.15.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Cosmo Pharmaceuticals SA
12.16 Daewoong Pharmaceutical
12.17 C.B. Fleet Company
12.18 Sucampo Pharmaceuticals
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF OPIOID INDUCED CONSTIPATION DRUGS
13.1 Industry Chain of Opioid Induced Constipation Drugs
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF OPIOID INDUCED CONSTIPATION DRUGS
14.1 Cost Structure Analysis of Opioid Induced Constipation Drugs
14.2 Raw Materials Cost Analysis of Opioid Induced Constipation Drugs
14.3 Labor Cost Analysis of Opioid Induced Constipation Drugs
14.4 Manufacturing Expenses Analysis of Opioid Induced Constipation Drugs
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Opioid Induced Constipation Drugs in This Report
1.2 Commercial Types of Opioid Induced Constipation Drugs
1.2.1 Lubiprostone
1.2.2 Methyl Naltrexone Bromide
1.2.3 Naldemedine
1.2.4 Alvimopan
1.2.5 Other
1.3 Downstream Application of Opioid Induced Constipation Drugs
1.3.1 Hospital Pharmacies
1.3.2 Retail Pharmacies
1.3.3 Online Pharmacies
1.4 Development History of Opioid Induced Constipation Drugs
1.5 Market Status and Trend of Opioid Induced Constipation Drugs 2013-2023
1.5.1 Global Opioid Induced Constipation Drugs Market Status and Trend 2013-2023
1.5.2 Regional Opioid Induced Constipation Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Opioid Induced Constipation Drugs 2013-2017
2.2 Sales Market of Opioid Induced Constipation Drugs by Regions
2.2.1 Sales Volume of Opioid Induced Constipation Drugs by Regions
2.2.2 Sales Value of Opioid Induced Constipation Drugs by Regions
2.3 Production Market of Opioid Induced Constipation Drugs by Regions
2.4 Global Market Forecast of Opioid Induced Constipation Drugs 2018-2023
2.4.1 Global Market Forecast of Opioid Induced Constipation Drugs 2018-2023
2.4.2 Market Forecast of Opioid Induced Constipation Drugs by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Opioid Induced Constipation Drugs by Types
3.2 Sales Value of Opioid Induced Constipation Drugs by Types
3.3 Market Forecast of Opioid Induced Constipation Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Opioid Induced Constipation Drugs by Downstream Industry
4.2 Global Market Forecast of Opioid Induced Constipation Drugs by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Opioid Induced Constipation Drugs Market Status by Countries
5.1.1 North America Opioid Induced Constipation Drugs Sales by Countries (2013-2017)
5.1.2 North America Opioid Induced Constipation Drugs Revenue by Countries (2013-2017)
5.1.3 United States Opioid Induced Constipation Drugs Market Status (2013-2017)
5.1.4 Canada Opioid Induced Constipation Drugs Market Status (2013-2017)
5.1.5 Mexico Opioid Induced Constipation Drugs Market Status (2013-2017)
5.2 North America Opioid Induced Constipation Drugs Market Status by Manufacturers
5.3 North America Opioid Induced Constipation Drugs Market Status by Type (2013-2017)
5.3.1 North America Opioid Induced Constipation Drugs Sales by Type (2013-2017)
5.3.2 North America Opioid Induced Constipation Drugs Revenue by Type (2013-2017)
5.4 North America Opioid Induced Constipation Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Opioid Induced Constipation Drugs Market Status by Countries
6.1.1 Europe Opioid Induced Constipation Drugs Sales by Countries (2013-2017)
6.1.2 Europe Opioid Induced Constipation Drugs Revenue by Countries (2013-2017)
6.1.3 Germany Opioid Induced Constipation Drugs Market Status (2013-2017)
6.1.4 UK Opioid Induced Constipation Drugs Market Status (2013-2017)
6.1.5 France Opioid Induced Constipation Drugs Market Status (2013-2017)
6.1.6 Italy Opioid Induced Constipation Drugs Market Status (2013-2017)
6.1.7 Russia Opioid Induced Constipation Drugs Market Status (2013-2017)
6.1.8 Spain Opioid Induced Constipation Drugs Market Status (2013-2017)
6.1.9 Benelux Opioid Induced Constipation Drugs Market Status (2013-2017)
6.2 Europe Opioid Induced Constipation Drugs Market Status by Manufacturers
6.3 Europe Opioid Induced Constipation Drugs Market Status by Type (2013-2017)
6.3.1 Europe Opioid Induced Constipation Drugs Sales by Type (2013-2017)
6.3.2 Europe Opioid Induced Constipation Drugs Revenue by Type (2013-2017)
6.4 Europe Opioid Induced Constipation Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Opioid Induced Constipation Drugs Market Status by Countries
7.1.1 Asia Pacific Opioid Induced Constipation Drugs Sales by Countries (2013-2017)
7.1.2 Asia Pacific Opioid Induced Constipation Drugs Revenue by Countries (2013-2017)
7.1.3 China Opioid Induced Constipation Drugs Market Status (2013-2017)
7.1.4 Japan Opioid Induced Constipation Drugs Market Status (2013-2017)
7.1.5 India Opioid Induced Constipation Drugs Market Status (2013-2017)
7.1.6 Southeast Asia Opioid Induced Constipation Drugs Market Status (2013-2017)
7.1.7 Australia Opioid Induced Constipation Drugs Market Status (2013-2017)
7.2 Asia Pacific Opioid Induced Constipation Drugs Market Status by Manufacturers
7.3 Asia Pacific Opioid Induced Constipation Drugs Market Status by Type (2013-2017)
7.3.1 Asia Pacific Opioid Induced Constipation Drugs Sales by Type (2013-2017)
7.3.2 Asia Pacific Opioid Induced Constipation Drugs Revenue by Type (2013-2017)
7.4 Asia Pacific Opioid Induced Constipation Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Opioid Induced Constipation Drugs Market Status by Countries
8.1.1 Latin America Opioid Induced Constipation Drugs Sales by Countries (2013-2017)
8.1.2 Latin America Opioid Induced Constipation Drugs Revenue by Countries (2013-2017)
8.1.3 Brazil Opioid Induced Constipation Drugs Market Status (2013-2017)
8.1.4 Argentina Opioid Induced Constipation Drugs Market Status (2013-2017)
8.1.5 Colombia Opioid Induced Constipation Drugs Market Status (2013-2017)
8.2 Latin America Opioid Induced Constipation Drugs Market Status by Manufacturers
8.3 Latin America Opioid Induced Constipation Drugs Market Status by Type (2013-2017)
8.3.1 Latin America Opioid Induced Constipation Drugs Sales by Type (2013-2017)
8.3.2 Latin America Opioid Induced Constipation Drugs Revenue by Type (2013-2017)
8.4 Latin America Opioid Induced Constipation Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Opioid Induced Constipation Drugs Market Status by Countries
9.1.1 Middle East and Africa Opioid Induced Constipation Drugs Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Opioid Induced Constipation Drugs Revenue by Countries (2013-2017)
9.1.3 Middle East Opioid Induced Constipation Drugs Market Status (2013-2017)
9.1.4 Africa Opioid Induced Constipation Drugs Market Status (2013-2017)
9.2 Middle East and Africa Opioid Induced Constipation Drugs Market Status by Manufacturers
9.3 Middle East and Africa Opioid Induced Constipation Drugs Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Opioid Induced Constipation Drugs Sales by Type (2013-2017)
9.3.2 Middle East and Africa Opioid Induced Constipation Drugs Revenue by Type (2013-2017)
9.4 Middle East and Africa Opioid Induced Constipation Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF OPIOID INDUCED CONSTIPATION DRUGS
10.1 Global Economy Situation and Trend Overview
10.2 Opioid Induced Constipation Drugs Downstream Industry Situation and Trend Overview
CHAPTER 11 OPIOID INDUCED CONSTIPATION DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Opioid Induced Constipation Drugs by Major Manufacturers
11.2 Production Value of Opioid Induced Constipation Drugs by Major Manufacturers
11.3 Basic Information of Opioid Induced Constipation Drugs by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Opioid Induced Constipation Drugs Major Manufacturer
11.3.2 Employees and Revenue Level of Opioid Induced Constipation Drugs Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 OPIOID INDUCED CONSTIPATION DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Ironwood Pharmaceuticals Inc
12.1.1 Company profile
12.1.2 Representative Opioid Induced Constipation Drugs Product
12.1.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Ironwood Pharmaceuticals Inc
12.2 Daiichi Sankyo Co Ltd
12.2.1 Company profile
12.2.2 Representative Opioid Induced Constipation Drugs Product
12.2.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Daiichi Sankyo Co Ltd
12.3 Pfizer
12.3.1 Company profile
12.3.2 Representative Opioid Induced Constipation Drugs Product
12.3.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Pfizer
12.4 Progenics Pharmaceuticals Inc
12.4.1 Company profile
12.4.2 Representative Opioid Induced Constipation Drugs Product
12.4.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Progenics Pharmaceuticals Inc
12.5 Shionogi & Co., Ltd
12.5.1 Company profile
12.5.2 Representative Opioid Induced Constipation Drugs Product
12.5.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Shionogi & Co., Ltd
12.6 Allergan Plc
12.6.1 Company profile
12.6.2 Representative Opioid Induced Constipation Drugs Product
12.6.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Allergan Plc
12.7 Nektar Therapeutics
12.7.1 Company profile
12.7.2 Representative Opioid Induced Constipation Drugs Product
12.7.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Nektar Therapeutics
12.8 Purdue Pharma
12.8.1 Company profile
12.8.2 Representative Opioid Induced Constipation Drugs Product
12.8.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Purdue Pharma
12.9 S.L.A. Pharma AG
12.9.1 Company profile
12.9.2 Representative Opioid Induced Constipation Drugs Product
12.9.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of S.L.A. Pharma AG
12.10 Mundipharma International Limited
12.10.1 Company profile
12.10.2 Representative Opioid Induced Constipation Drugs Product
12.10.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Mundipharma International Limited
12.11 Ono Pharmaceutical Co., Ltd
12.11.1 Company profile
12.11.2 Representative Opioid Induced Constipation Drugs Product
12.11.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Ono Pharmaceutical Co., Ltd
12.12 Takeda Pharmaceutical Company Limited
12.12.1 Company profile
12.12.2 Representative Opioid Induced Constipation Drugs Product
12.12.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Takeda Pharmaceutical Company Limited
12.13 Theravance Biopharma Inc
12.13.1 Company profile
12.13.2 Representative Opioid Induced Constipation Drugs Product
12.13.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Theravance Biopharma Inc
12.14 Valeant Pharmaceuticals International
12.14.1 Company profile
12.14.2 Representative Opioid Induced Constipation Drugs Product
12.14.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Valeant Pharmaceuticals International
12.15 Cosmo Pharmaceuticals SA
12.15.1 Company profile
12.15.2 Representative Opioid Induced Constipation Drugs Product
12.15.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Cosmo Pharmaceuticals SA
12.16 Daewoong Pharmaceutical
12.17 C.B. Fleet Company
12.18 Sucampo Pharmaceuticals
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF OPIOID INDUCED CONSTIPATION DRUGS
13.1 Industry Chain of Opioid Induced Constipation Drugs
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF OPIOID INDUCED CONSTIPATION DRUGS
14.1 Cost Structure Analysis of Opioid Induced Constipation Drugs
14.2 Raw Materials Cost Analysis of Opioid Induced Constipation Drugs
14.3 Labor Cost Analysis of Opioid Induced Constipation Drugs
14.4 Manufacturing Expenses Analysis of Opioid Induced Constipation Drugs
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference